The presence of hematogones marks a group with good prognosis in AML/advanced MDS patients. The Kaplan-Meier estimates of OS and RFS in HG⁺ and HG⁻ patients in AML or advanced MDS differentiated with their remission status before HSCT. Significantly better OS and RFS were seen in HG⁺ groups irrespective of their remission status.